ARTICLE | Emerging Company Profile
Company aims to keep patients out of hospital with a dual-mechanism rescue treatment to prevent vaso-occlusive crises
By Richard Guy, Biopharma Analyst
October 31, 2024 12:22 AM UTC
IHP Therapeutics believes its self-administered rescue treatment will be powerful enough to halt painful VOCs in sickle cell disease patients based on its dual mechanism of action. The company has raised $15 million in seed and grant funding, and has launched a $35 million series A.
CEO Rinko Ghosh told BioCentury that IHP Therapeutics Inc. began with a heparin-based treatment for COVID-19, then pivoted to sickle cell disease. Heparin, a sulfated polysaccharide, is a multi-functional molecule, with its anticoagulant and anti-inflammatory properties forming much of the basis of its development in COVID-19. As the pandemic waned, Ghosh said IHP saw an opportunity instead to tune heparin’s properties specifically for sickle cell disease. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653883/ihp-creating-an-epipen-for-sickle-cell-disease